Siemens features new heart SPECT technology, opens more radiopharmacies
Siemens Healthcare is highlighting its work-in-progress IQ-SPECT as the company’s newest Symbia feature, which enables a comprehensive cardiac evaluation including perfusion, attenuation correction and calcium scoring in just five minutes, at the 2008 Society of Nuclear Medicine (SNM) meeting, June 14-18, in New Orleans.
The company has also opened two new radiopharmacies in Las Vegas and Pittsburgh to ensure that more U.S. healthcare facilities have access to the PET/CT technology.
“IQ-SPECT offers enhanced cardiac image quality and thus offers physicians more confident diagnostic ability because of decreased patient movement. We expect this new capability to provide organ specific, cardiac imaging on general purpose systems, as it could potentially expand to other organs as well,” according to Michael Reitermann, CEO of molecular imaging at Siemens Medical Solutions USA.
The company said its IQ-SPECT technology is achieved with Smartzoom, a ‘smart’ collimator that magnifies the heart while imaging the rest of the torso under traditional conditions, according to the company. The flexible mechanics of the Symbia S and T gantries allow an organ centric detector rotation that can zero in on the organ of interest; in this case, the heart.
The two new radiopharmacies will produce imaging biomarkers, an important component of PET/CT tests used to diagnose cancer and cardiac and neurological ailments, according to the company.
The expansion into Las Vegas and Pittsburgh bolsters Siemens' goal to provide PETNet services to all U.S. hospitals and imaging centers.
Also at the SNM show, Siemens is featuring early adopters as testament to the power of its new technology, and highlighting how HD-PET is enabling improved patient care all over the world.
Siemens said its HD-PET is the PET technology to offer sharper, clearly defined images. The clarity achieved by HD-PET is the result of a proprietary technology that optimizes the elements of image uniformity, resolution and contrast, the company said.
“HD-PET is a real technological advancement for challenging imaging situations, in particular, for small lesions and breath-dependent lesions,” said W. Mohnike, MD, PhD, from the Diagnostic Therapy Center in Berlin.
The company has also opened two new radiopharmacies in Las Vegas and Pittsburgh to ensure that more U.S. healthcare facilities have access to the PET/CT technology.
“IQ-SPECT offers enhanced cardiac image quality and thus offers physicians more confident diagnostic ability because of decreased patient movement. We expect this new capability to provide organ specific, cardiac imaging on general purpose systems, as it could potentially expand to other organs as well,” according to Michael Reitermann, CEO of molecular imaging at Siemens Medical Solutions USA.
The company said its IQ-SPECT technology is achieved with Smartzoom, a ‘smart’ collimator that magnifies the heart while imaging the rest of the torso under traditional conditions, according to the company. The flexible mechanics of the Symbia S and T gantries allow an organ centric detector rotation that can zero in on the organ of interest; in this case, the heart.
The two new radiopharmacies will produce imaging biomarkers, an important component of PET/CT tests used to diagnose cancer and cardiac and neurological ailments, according to the company.
The expansion into Las Vegas and Pittsburgh bolsters Siemens' goal to provide PETNet services to all U.S. hospitals and imaging centers.
Also at the SNM show, Siemens is featuring early adopters as testament to the power of its new technology, and highlighting how HD-PET is enabling improved patient care all over the world.
Siemens said its HD-PET is the PET technology to offer sharper, clearly defined images. The clarity achieved by HD-PET is the result of a proprietary technology that optimizes the elements of image uniformity, resolution and contrast, the company said.
“HD-PET is a real technological advancement for challenging imaging situations, in particular, for small lesions and breath-dependent lesions,” said W. Mohnike, MD, PhD, from the Diagnostic Therapy Center in Berlin.